Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Implementing routine testing for severe combined immunodeficiency within Wisconsin's newborn screening program.

Baker MW, Laessig RH, Katcher ML, Routes JM, Grossman WJ, Verbsky J, Kurtycz DF, Brokopp CD.

Public Health Rep. 2010 May-Jun;125 Suppl 2:88-95.

2.

Statewide newborn screening for severe T-cell lymphopenia.

Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, Baker MW.

JAMA. 2009 Dec 9;302(22):2465-70. doi: 10.1001/jama.2009.1806.

PMID:
19996402
3.

Regulatory compliance for point-of-care testing: 2009 United States perspective.

Ehrmeyer SS, Laessig RH.

Clin Lab Med. 2009 Sep;29(3):463-78. doi: 10.1016/j.cll.2009.06.012.

PMID:
19840680
4.

Development of a routine newborn screening protocol for severe combined immunodeficiency.

Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp CD, Kurtycz DF, Cogley MF, Litsheim TJ, Katcher ML, Routes JM.

J Allergy Clin Immunol. 2009 Sep;124(3):522-7. doi: 10.1016/j.jaci.2009.04.007. Epub 2009 May 31.

PMID:
19482345
5.

Point-of-care testing, medical error, and patient safety: a 2007 assessment.

Ehrmeyer SS, Laessig RH.

Clin Chem Lab Med. 2007;45(6):766-73. Review.

PMID:
17579530
6.

Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.

Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM.

J Pediatr. 2005 Sep;147(3 Suppl):S73-7.

PMID:
16202788
7.

Memories, memories.

Laessig RH.

MLO Med Lab Obs. 2005 Jun;37(6):6. No abstract available.

PMID:
16028471
8.

Polybrominated diphenyl ethers (PBDEs): new pollutants-old diseases.

Siddiqi MA, Laessig RH, Reed KD.

Clin Med Res. 2003 Oct;1(4):281-90. Review.

9.

CLIA 2003's new concept: equivalent quality control.

Laessig RH, Ehrmeyer SS.

MLO Med Lab Obs. 2005 Jan;37(1):32-4. No abstract available.

PMID:
15743146
10.

Multiplexed genetic analysis using an expanded genetic alphabet.

Johnson SC, Marshall DJ, Harms G, Miller CM, Sherrill CB, Beaty EL, Lederer SA, Roesch EB, Madsen G, Hoffman GL, Laessig RH, Kopish GJ, Baker MW, Benner SA, Farrell PM, Prudent JR.

Clin Chem. 2004 Nov;50(11):2019-27. Epub 2004 Aug 19.

11.

Has compliance with CLIA requirements really improved quality in US clinical laboratories?

Ehrmeyer SS, Laessig RH.

Clin Chim Acta. 2004 Aug 2;346(1):37-43.

PMID:
15234634
12.

Screening newborns for congenital disorders.

Hoffman GL, Laessig RH.

WMJ. 2003;102(6):45-50.

13.

The current and future roles of the Wisconsin State Laboratory of Hygiene.

Laessig RH.

WMJ. 2003;102(6):17-23. No abstract available.

14.

Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program.

Lee DS, Rosenberg MA, Peterson A, Makholm L, Hoffman G, Laessig RH, Farrell PM.

J Pediatr. 2003 Jun;142(6):617-23.

PMID:
12838188
15.

Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.

Insinga RP, Laessig RH, Hoffman GL.

J Pediatr. 2002 Oct;141(4):524-31. Erratum in: J Pediatr. 2003 Jan;142(1):56..

PMID:
12378192
16.

Electronic "Quality Control" (EQC): is it just for unit use devices?

Ehrmeyer SS, Laessig RH.

Clin Chim Acta. 2001 May;307(1-2):95-9.

PMID:
11369342
17.

Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group.

Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, Hoffman G, Laessig RH, Splaingard ML.

Pediatrics. 2001 Jan;107(1):1-13.

PMID:
11134427
18.

Effect of legislation (CLIA'88) on setting quality specifications for US laboratories.

Ehrmeyer SS, Laessig RH.

Scand J Clin Lab Invest. 1999 Nov;59(7):563-7.

PMID:
10667700
20.

Point-of-care testing technology. Is quality control still relevant?

Ehrmeyer SS, Laessig RH.

MLO Med Lab Obs. 1997 Sep;Suppl:10-3; quiz 34-5. No abstract available.

PMID:
10174088
21.

Quality: the next six months.

Laessig RH, Ehrmeyer SS.

Clin Chem. 1997 May;43(5):903-7. Review.

22.

Regulatory requirements (CLIA '88, JCAHO, CAP) for decentralized testing.

Ehrmeyer SS, Laessig RH.

Am J Clin Pathol. 1995 Oct;104(4 Suppl 1):S40-9. Review.

PMID:
7484948
23.

Newborn screening for cystic fibrosis in Wisconsin: first application of population-based molecular genetics testing.

Farrell PM, Aronson RA, Hoffman G, Laessig RH.

Wis Med J. 1994 Aug;93(8):415-21.

PMID:
7975706
24.
25.

Review of actual proficiency-testing performance under CLIA '67 (March 14, 1990) rules: perspective from the first year's data.

Lanphear BJ, Burmeister BJ, Ehrmeyer SS, Laessig RH, Hassemer DJ.

Clin Chem. 1992 Jul;38(7):1254-9; discussion 1268-72.

26.

Limitations of proficiency testing under CLIA '67.

Laessig RH, Ehrmeyer SS, Lanphear BJ, Burmeister BJ, Hassemer DJ.

Clin Chem. 1992 Jul;38(7):1237-44; discussion 1245-50.

27.

The effect of dentures and denture adhesives on mouth alcohol retention.

Harding PM, McMurray MC, Laessig RH, Simley DO 2nd, Correll PJ, Tsunehiro JK.

J Forensic Sci. 1992 Jul;37(4):999-1007.

PMID:
1506841
30.

Are clinical laboratory proficiency tests as good as they can be?

Tietz NW, Rodgerson DO, Laessig RH.

Clin Chem. 1992 Apr;38(4):473-5.

31.

Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin.

Hassemer DJ, Laessig RH, Hoffman GL, Farrell PM.

Pediatr Pulmonol Suppl. 1991;7:76-83.

PMID:
1782137
32.

Current issues in neonatal screening for cystic fibrosis and implications of the CF gene discovery.

Farrell PM, Mischler EH, Fost NC, Wilfond BS, Tluczek A, Gregg RG, Bruns WT, Hassemer DJ, Laessig RH.

Pediatr Pulmonol Suppl. 1991;7:11-8. Review.

PMID:
1782123
33.
34.
35.

Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels.

Rock MJ, Mischler EH, Farrell PM, Wei LJ, Bruns WT, Hassemer DJ, Laessig RH.

Pediatrics. 1990 Jun;85(6):1001-7.

PMID:
2187173
36.

Medical need for quality specifications within laboratory medicine.

Laessig RH.

Ups J Med Sci. 1990;95(3):233-44. No abstract available.

PMID:
2100400
37.

Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test.

Rock MJ, Mischler EH, Farrell PM, Bruns WT, Hassemer DJ, Laessig RH.

Pediatr Pulmonol. 1989;6(1):42-8.

PMID:
2704582
38.

Testing cholesterol accuracy. Performance of several common laboratory instruments.

Koch DD, Hassemer DJ, Wiebe DA, Laessig RH.

JAMA. 1988 Nov 4;260(17):2552-7.

PMID:
3172430
41.

Proficiency testing programs--promises, progress, and problems. A 40-year prospective.

Laessig RH, Ehrmeyer SS.

Arch Pathol Lab Med. 1988 Apr;112(4):329-33.

PMID:
3355326
42.
43.
44.
45.

The sanitized Systéme International (SI) d'Unités.

Doumas BT, Laessig RH, Larson FC.

Clin Chim Acta. 1987 Jul 30;167(1):113-6. No abstract available.

PMID:
3665085
46.
48.

Quality control and quality assurance.

Laessig RH, Ehrmeyer SS, Hassemer DJ.

Clin Lab Med. 1986 Jun;6(2):317-27.

PMID:
3720254
49.
50.

Alternative statistical approach to evaluating interlaboratory performance.

Ehrmeyer SS, Laessig RH.

Clin Chem. 1985 Jan;31(1):106-8.

Supplemental Content

Loading ...
Support Center